EF001 免責聲明 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | | | --- | --- | | 股票發行人現金股息公告 | | | 發行人名稱 SISRAM MEDICAL LTD 復銳醫療科技有限公司* | | | 股份代號 | 01696 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 截至二零二四年十二月三十一日止年度的末期股息 | | | 公告日期 | 2025年3月19日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2024年12月31日 | | 宣派股息的報告期末 | 2024年12月31日 | | 宣派股息 | 每 股 0.126 HKD | | 股東批准日期 | 不適用 | | 香港過戶登記處相關信息 | | | 派息金額及公司預設派發貨幣 | 每 股 0.126 HKD | | ...

Financial Performance - For the fiscal year ending December 31, 2024, revenue was $349.1 million, a decrease of 2.8% compared to the previous year[4] - Net profit for the year was $28.8 million, down 12.6% year-on-year[4] - Total revenue for the year ending December 31, 2024, was $349,112 thousand, a decrease of 2% from $359,292 thousand in 2023[18] - Revenue from North America decreased by 12% to $137,398 thousand in 2024 from $156,891 thousand in 2023[18] - Gross profit decreased from $219.5 million in 2023 to $216.7 million in 2024, a reduction of approximately $2.8 million, while gross margin improved to 62.1%, up from 61.1% in 2023[50] - The group reported a pre-tax profit of $32,541,000 for 2024, down from $37,130,000 in 2023, reflecting a decline of approximately 12.5%[34] - Adjusted net profit decreased by 22.3% from $36.9 million in 2023 to $28.7 million in 2024, with adjusted net profit margin dropping from 10.3% to 8.2%[100] Revenue Breakdown - Direct sales accounted for 87% of total revenue, up from 78% in the previous year[4] - Revenue from the Asia-Pacific, Europe, Middle East, and Africa regions was $116.2 million, $50.5 million, and $34.6 million respectively, representing increases of 6.0%, 0.7%, and 27.1% year-on-year[4] - North America revenue decreased by 12.4% year-on-year due to the ongoing impact of a high-interest environment[4] - The Asia-Pacific region saw a revenue increase of 6.0%, contributing 33.3% to total revenue in 2024[83] - Europe revenue rose by 0.7% from $50.2 million in 2023 to $50.5 million in 2024, mainly due to the successful "Go-Direct" strategy in the UK[86] - Middle East and Africa revenue surged by 27.1% from $27.2 million in 2023 to $34.6 million in 2024, supported by the launch of Soprano Titanium™ and strong performance of the Alma Harmony™ product line[86] - Latin America revenue decreased by 32.3% from $15.3 million in 2023 to $10.4 million in 2024, impacted by political instability in key regions[86] Expenses and Costs - Research and development expenses were $15.9 million, down from $18.0 million in the previous year[5] - The group's cost of goods sold decreased to $100,529,000 in 2024 from $103,947,000 in 2023, reflecting a reduction of about 4%[27] - Total sales and distribution expenses increased by 4.9% from $125.3 million in 2023 to $131.5 million in 2024, mainly due to expenses related to new direct sales office operations[90] - Financing costs totaled $2,455,000 in 2024, slightly up from $2,445,000 in 2023, showing a marginal increase of about 0.4%[29] Dividends and Shareholder Returns - The board declared a final dividend of HKD 0.126 per share (tax included) for the fiscal year ending December 31, 2024[3] - The company declared a final dividend of HKD 0.126 per share for the year ending December 31, 2024, down from HKD 0.158 in 2023, indicating a decrease of approximately 20%[35] Assets and Liabilities - Total assets amounted to $627.3 million, with total liabilities of $142.5 million as of December 31, 2024[8] - Non-current assets increased to $365,666 thousand in 2024 from $345,671 thousand in 2023, representing a growth of 5.5%[19] - Trade receivables increased to $111,139,000 in 2024 from $98,711,000 in 2023, representing a growth of about 12.5%[40] - The net value of trade receivables after impairment was $107,312,000 in 2024, compared to $96,365,000 in 2023, marking an increase of about 11.4%[40] Strategic Initiatives - The company launched three new products in new regions, including the Alma Harmony™, which has seen strong market demand and is one of the most successful product launches in the company's history[56] - The company established a strategic partnership with Prollenium to distribute the Revanesse® dermal filler series in key markets including Germany, Austria, Switzerland, Australia, and New Zealand[48] - The company aims to maintain sufficient cash levels to support business growth and strategic investments in core technology development and clinical research[56] - The company is transitioning its business model from product-driven to clinic-centered, focusing on high-value advanced product categories[62] - The company plans to commercialize DAXXIFY® in mainland China and expand the launch of injection filler products in new regions[74] Research and Development - Research and development expenditure amounted to $15.9 million during the reporting period[56] - The company conducted four additional clinical studies and published 20 clinical papers during the reporting period, showcasing its commitment to clinical research[59] - Research and development expenses decreased from $18.0 million in 2023 to $15.9 million in 2024, attributed to successful regulatory certification and improved labor productivity[92] Market Performance - Global sales and distribution network achieved total revenue of $349.1 million in 2024, a decrease of 2.8% compared to 2023, primarily due to challenging economic conditions in North America and Latin America[50] - The injection filler business generated $9.8 million in revenue, a decrease of 2.6% compared to the previous year, due to a focus on developing new generation products[82] Governance and Compliance - The audit committee has reviewed the group's annual performance and the financial statements prepared in accordance with international financial reporting standards for the year ending December 31, 2024[136] - The company has complied with all applicable principles and code provisions of the Corporate Governance Code during the reporting period[133]

Sisram Medical Ltd 復䢇醫療科技有限公司* 非執行董事 吳以芳先生 馮蓉麗女士 獨立非執行董事 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 董事名單與其角色及職能 復銳醫療科技有限公司董事會（「董事會」）成員載列如下（自二零二五年三月十九日 起生效）： 執行董事 劉毅先生 （主席） Lior Moshe DAYAN先生 （首席執行官） 李家宏先生 （首席財務官） 方香生先生 陳志峰先生 陳怡芳女士 廖啟宇先生 相關董事委員會成員載列如下（自二零二五年三月十九日起）： C 委員會主席 M 委員會成員 香港，二零二五年三月十九日 * 僅供識別 | 董事 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 劉毅先生 | | M | C | | DAYAN先生 Lior Moshe | | | | | 李家宏先生 | | | | | 吳以芳先生 | | | | | 馮蓉麗女士 | | | | | 方香生先生 | C | M | M | | 陳志峰先生 | M | C | M | | 陳怡芳女士 | M | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* – 1 – 李先生已根據本公司組織章程細則與本公司訂立委任書，任期自二零二五年三月 十九日開始，將繼續有效直至任何一方向另一方發出三個月事先書面通知予以終 止，並須遵守本公司組織章程細則項下的董事退任及輪換條文。根據本公司組織 章程細則，李先生將擔任本公司執行董事直至本公司舉行下屆股東週年大會為 止，然後於大會上競選連任。李先生將不會就擔任本公司執行董事而向本公司收 取任何薪酬。 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 委任董事 復銳醫療科技有限公司*（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事 會」）宣佈，自二零二五年三月十九日起，李家宏先生（「李先生」）已獲委任為本公 司執行董事。 李先生，46歲，於二零二四年十月二十九日加入本集團，擔任本公司首席財務 官。彼負責本集團財務營運、融 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 香港，二零二五年三月七日 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 董事會會議召開日期 復銳醫療科技有限公司*（「本公司」及其附屬公司「本集團」）董事會（「董事會」）兹通 告謹定於二零二五年三月十九日（星期三）舉行本公司董事會會議，以考慮及通過 本集團截至二零二四年十二月三十一日止年度的全年業績，及建議之末期股息（如 有），以及處理其他事項。 代表董事會 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香生先生、陳志 峰先生、陳怡芳女士及廖啟宇先生。 * 僅供識別 ...

Investment Rating - The report assigns a "Buy" rating for Sisram Medical (复锐医疗科技) as a first-time coverage [6][7]. Core Views - Sisram Medical is positioned as a global leader in energy source devices, expanding its presence in the beauty and health ecosystem. The company has diversified its business into injection fillers, personal care, and digital dentistry, leveraging its strong R&D capabilities and market presence [6][18]. - The Chinese medical aesthetics market is experiencing stable growth, with the light medical aesthetics segment showing promising prospects. The company is well-positioned to capitalize on this trend through its established product lines and market strategies [6][45]. Financial Data and Profit Forecast - Total revenue projections for Sisram Medical are as follows: - 2023: $359.29 million (YoY +1.36%) - 2024E: $368.57 million (YoY +2.58%) - 2025E: $429.16 million (YoY +16.44%) - 2026E: $494.15 million (YoY +15.15%) [5][6] - Net profit forecasts are: - 2023: $31.50 million (YoY -21.59%) - 2024E: $30.07 million (YoY -4.53%) - 2025E: $39.09 million (YoY +29.99%) - 2026E: $47.16 million (YoY +20.64%) [5][6] - Earnings per share (EPS) estimates are: - 2023: $0.07 - 2024E: $0.06 - 2025E: $0.08 - 2026E: $0.10 [5][6] Business Expansion and Market Position - Sisram Medical has a solid foundation in energy source devices and a promising outlook for injection fillers. The company is expanding its business into digital dentistry and personal care, aiming to create a comprehensive beauty and health ecosystem [6][18]. - The company has established a strong direct sales network, with 78% of its revenue coming from direct sales in 2023, and is actively expanding its global reach [6][24]. Market Trends and Growth Potential - The light medical aesthetics market in China is projected to grow significantly, with a CAGR of 12.8% expected from 2024 to 2030. The non-surgical segment is anticipated to account for 65% of the market by 2030 [46]. - The energy source device market is expected to maintain rapid growth, driven by consumer demand for non-invasive procedures such as photorejuvenation and hair removal [6][45].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （股份代號：1696） 更改香港主要營業地點的地址 復銳醫療科技有限公司*（「本公司」）董事會（「董事會」）謹此宣佈，由二零二五年一 月十日起，本公司於香港的主要營業地點的地址將由香港九龍觀塘道348號宏利廣 場5樓遷往： 主席 劉毅 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） 香港，二零二五年一月十七日 香港銅鑼灣希慎道33號利園一期19樓1917室 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 於本公告日期，本公司董事會包括執行董事劉毅先生及Lior Moshe DAYAN先 生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香生先生、陳志峰 先生、陳怡芳女士及廖啟宇先生。 * 僅供識別 ...

（股份代號：1696） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） – 1 – 股東及投資者於買賣本公司證券時務請審慎行事。 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 香港，二零二四年十二月四日 自願公告 ALMA獲授醫療器械法規認證 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 本公司欣然宣佈，於二零二四年下半年度，Alma Lasers Ltd.（「Alma」，本公司主 要營運附屬公司）已分別就其品質管理體系及其兩款應用於皮膚科的醫療產品 Alma Harmony™及Alma Hybrid™獲得歐盟醫療器械法規(EU) 2017/745 （European Union Medical Device Regulation (EU) 2017/745）（「醫療器械法 規」） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 香港，二零二四年十一月五日 於本公告日期，本公司董事會成員包括執行董事劉毅先生及Lior Moshe DAYAN 先生；非執行董事吳以芳先生及馮蓉麗女士；獨立非執行董事方香生先生、陳志 峰先生、陳怡芳女士及廖啟宇先生。 * 僅供識別 本公司欣然宣佈推出其屢獲殊榮的美容平台Alma Harmony的全新版本（「新Alma Harmony」）。 新Alma Harmony採用現代化設計，並進行了大幅升級，為客戶提供更多的治療 選擇和簡單智能的使用體驗。其革新的患者個性化功能融合了五項最受歡迎的技 術及增強的能量，能夠提供全面的治療方案。 新Alma Harmony的設計重點在於提升效率、簡易性及易用 ...

Investment Rating - The investment rating for the company is upgraded to "Accumulate" with a target price of 3.75 HKD [1]. Core Views - The medical beauty business is steadily growing, with strong performance in the Asia-Pacific and European markets [1]. - The company reported a revenue of 1.209 billion HKD for H1 2024, a decrease of 1.4% year-on-year, and a net profit of 78 million HKD, down 42.05% year-on-year [1]. - The medical beauty segment generated 1.056 billion HKD in revenue, accounting for 88.5% of total revenue, with a year-on-year growth of 1.3% [1]. - The company is focusing on new product launches, which have been well received in the market, and is expanding its commercialization efforts in the Asia-Pacific region [1]. Business Segment Summary - **Medical Beauty Business**: Revenue reached 1.056 billion HKD, with a year-on-year growth of 1.3%. The revenue mainly comes from classic devices like Soprano, Harmony, Opus, Accent, and Hybrid [1]. - **Injectable Fillers**: Revenue was 31.949 million HKD, a decrease of 7.5% year-on-year, due to a shift in focus towards new product launches [1]. - **Dental Business**: Revenue was 19.952 million HKD, down 47.0% year-on-year, as this segment is still in the incubation phase and facing demand-side pressures [1]. - **Service and Other Businesses**: Revenue was 85.271 million HKD, a decrease of 14.1% year-on-year [1]. Regional Performance Summary - **North America**: Revenue was 474 million HKD, accounting for 39.7% of total revenue, down 15.7% year-on-year due to rising credit costs affecting customer purchasing decisions [1]. - **Asia-Pacific**: Revenue was 396 million HKD, accounting for 33.3% of total revenue, with a year-on-year growth of 15.5% driven by strong performance from Alma China [1]. - **Europe**: Revenue was 170 million HKD, accounting for 14.2% of total revenue, with a year-on-year growth of 10.0% due to the transition to direct sales in the UK market [1]. - **Middle East and Africa**: Revenue was 109 million HKD, accounting for 9.1% of total revenue, with a year-on-year growth of 10.9% [1]. - **Latin America**: Revenue was 44.661 million HKD, accounting for 3.7% of total revenue, down 20.3% year-on-year [1]. Profitability and Cost Structure - The company's gross margin for H1 2024 was 62.41%, an increase of 1.06 percentage points year-on-year, primarily due to a higher proportion of direct sales [1]. - The selling expense ratio increased by 2.59 percentage points year-on-year due to increased sales and marketing activities [1]. - The management expense ratio increased by 1.49 percentage points year-on-year due to expenses related to new office operations [1]. - R&D expense ratio remained stable year-on-year [1]. Future Outlook - The company expects revenues for 2024-2026 to be 2.569 billion HKD, 3.002 billion HKD, and 3.505 billion HKD respectively, with net profits of 215 million HKD, 280 million HKD, and 339 million HKD respectively [1].